Streetbeat News

SYNH

Syneos Health Inc

CEO

Michael Bell

Employees

18,607

Industry

Research and Development in Biotechnology

inc research/inventiv health has become syneos health, the only fully integrated end-to-end clinical and commercial solution organization. we are purpose-built for biopharmaceutical acceleration, creating better, smarter, faster ways to help clients navigate an increasingly complex marketplace. our new business addresses today’s market realities through clinical and commercial sharing expertise and data and insights to meet the needs of emerging and large global biopharmaceutical companies.

Open

42.98

Mkt cap

4.5B

Volume

6.7M

High

42.99

P/E Ratio

61.40

52-wk high

52.23

Low

42.97

Div yield

N/A

52-wk low

22.89

Syneos Health, Inc. has announced the appointment of Colin Shannon as the new CEO, succeeding Michelle Keefe. Keefe will continue her tenure with the company as a key member of the Executive Leadership Team. Both Shannon and Keefe will remain on the Board of Directors.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:18 pm

Civitas Resources is set to join the S&P MidCap 400 index. This inclusion could potentially increase the visibility and trading volume of the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 9:44 pm

Syneos Health (SYNH) has announced a strategic collaboration with Oracle (ORCL) to expand their relationship. The collaboration will utilize Oracle's Cerner Learning Health Network and study startup solutions to reduce patient recruitment time for clinical studies and increase diversity in patient populations.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 11:36 am

Syneos Health (NASDAQ:SYNH) has signed an agreement with Aotearoa Clinical Trials to expand its clinical trial capabilities in New Zealand. Aotearoa Clinical Trials will join the Syneos Health Catalyst Site Program, which aims to strengthen collaborations with clinical research sites worldwide. The partnership will enable sites, sponsors, and patients to collaborate in multiple therapeutic areas.

Portfolio Pulse from Happy Mohamed

August 10, 2023 | 2:53 pm

Syneos Health, Inc. (NASDAQ:SYNH) stockholders have approved an agreement to take the company private through an acquisition by a consortium of private investment firms, including Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital. The transaction, expected to close in the second half of 2023, will see stockholders receive $43.00 in cash for each share of Syneos Health common stock owned at the closing of the transaction.

Portfolio Pulse from Happy Mohamed

August 04, 2023 | 11:13 am

Click Therapeutics has launched its second active randomized clinical trial in partnership with Syneos Health (NASDAQ:SYNH) to test digital interventions in migraine patients. The trial will evaluate the efficacy and safety of digital therapeutics for the prevention of episodic migraine in patients receiving CGRP inhibitor therapy. The trial will be fully remote and decentralized, allowing patients to participate from anywhere using their own devices.

Portfolio Pulse from Happy Mohamed

August 04, 2023 | 11:08 am

FSD Pharma has announced that an arbitration panel found Syneos Health to have failed in using commercially reasonable efforts in conducting a trial for FSD 201.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 9:07 pm

OpGen's subsidiary Ares Genetics has maintained its patent titled 'Genetic Resistance Prediction Against Antimicrobial Drugs In Microorganism Using Structural Changes In The Genome' in Europe.

Portfolio Pulse from Bill Haddad

June 26, 2023 | 11:37 am

Syneos Health has announced a collaboration with uMotif, where uMotif will provide eCOA and ePRO services for Syneos. The companies will also develop and deploy an exclusive platform.

Portfolio Pulse from Bill Haddad

June 26, 2023 | 11:35 am

FivepHusion, a clinical-stage biotechnology company, has announced a collaboration with Treehill Partners and Syneos Health (NASDAQ:SYNH) to develop and bring a novel, enhanced chemotherapeutic product to market.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 7:13 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.